ctDNA testing

DIAGNOSTIC_TEST3 trials

Sponsors

Hunan Cancer Hospital, NSABP Foundation Inc, Memorial Sloan Kettering Cancer Center

Conditions

Circulating Tumor DNAColo-rectal CancerEndometrial CancerGene AbnormalityMetastatic Breast Cancer

Phase 2

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

RecruitingNCT07058012

NSABP Foundation IncColo-rectal Cancer

Start: 2026-04-17End: 2029-06-01Target: 79Updated: 2026-09-03

Unknown Phase

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

CompletedNCT05079074

Hunan Cancer HospitalCirculating Tumor DNA, Gene Abnormality, Metastatic Breast Cancer

Start: 2016-12-01End: 2021-06-30Updated: 2022-06-22

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

RecruitingNCT07270666

Memorial Sloan Kettering Cancer CenterEndometrial Cancer

Start: 2025-11-25End: 2027-11-01Target: 30Updated: 2026-07-13

Related Papers

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

2026-06-25

NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.

Journal of Clinical Oncology2026-05-28

Abstract 7849: Real-world landscape analysis of circulating tumor DNA minimal residual disease as a clinical trial endpoint in breast cancer.

Cancer Research2026-04-03

NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.

Journal of Clinical Oncology2026-01-10

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC

Frontiers in Endocrinology2022-11-285 citations

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.

2022-07-1926 citations

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study.

2022-07-186 citations